Core Insights - Polaryx Therapeutics, Inc. has appointed three new members to its Board of Directors, enhancing its expertise in scientific research, clinical development, finance, and corporate strategy as it progresses as a public company [1][2][3] Board Appointments - Mitchel Berger, M.D., Francis A. Braun III, CPA, and Charles Ryan, J.D., Ph.D. have been appointed to the Board, effective January 29, 2026, while Andrew O has ceased to serve [1][2] - The new board members bring extensive experience: Dr. Berger is a prominent figure in neuro-oncology, Mr. Braun has a strong background in finance and advisory roles, and Dr. Ryan has significant experience in biotechnology and regulatory affairs [3][4][5][6] Company Milestones - Polaryx is advancing its lead candidate, PLX-200, into an IND-approved SOTERIA Phase 2 basket trial, marking a significant near-term milestone for the company [2][3] - The company focuses on developing therapies for rare, pediatric lysosomal storage disorders (LSDs), aiming to address significant unmet medical needs [7]

AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 ___________________________ Polaryx Therapeutics, Inc. (Exact name of registrant as specified in its charter) ___________________________ (State or other jurisdiction of incorporation or organization) As filed with the Securities and Exchange Commission on January 27, 2026 Registration No. 333-291681 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Primary Standard Industrial Classification Code Numbe ...

As filed with the Securities and Exchange Commission on January 13, 2026 Registration No. 333-291681 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 ___________________________ Polaryx Therapeutics, Inc. (Exact name of registrant as specified in its charter) ___________________________ (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Numbe ...

As filed with the Securities and Exchange Commission on November 20, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 ___________________________ Polaryx Therapeutics, Inc. (Exact name of registrant as specified in its charter) ___________________________ (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Nevada 2834 47-339365 ...